Labopharm Inc. (DDSS) has granted GlaxoSmithKline (GSK) exclusive rights to distribute its once-daily tramadol product in Mexico. The Laval, Que. pharmaceutical company said the agreement expands the existing licensing and distribution arrangement between it and Glaxo, entered into in September 2005, for 20 Latin American and Caribbean countries.
MarketWatch
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
FDA Grants PMA for QView Medical’s Automated Breast Ultrasound System
The device is meant for breast screening in asymptomatic dense breasted women whose mammograms returned negative.
Sandoz Announces Voluntary Recall of Potentially Contaminated Losartan
The affected product was distributed after October 8, according to the FDA.
FDAnews Drug Daily Bulletin
LABOPHARM GRANTS GLAXO ONCE-DAILY TRAMADOL RIGHTS IN MEXICO
June 1, 2006
